# Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer

> **NCT04152057** · PHASE1,PHASE2 · UNKNOWN · sponsor: **West China Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer
- HER2 Positive
- Combination Chemotherapy

## Interventions

- **DRUG:** Pyrotinib Maleate Tablets
- **DRUG:** Albumin Paclitaxel
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT04152057
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11
- **Primary completion:** 2020-04
- **Final completion:** 2021-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04152057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04152057, "Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04152057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*